Immunotherapy for Elderly Patients With Chronic Osteoporotic Pain
Unknown statusPhase 4NCT04524169
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Osteoporotic pain is the most common clinical symptom in elderly patients. The course of pain is prolonged and the effect of clinical treatment is limited. This study will observe the therapeutic effect of thymosin alpha 1 on elderly patient with osteoporotic pain and explore its immunotherapy mechanism.
Study details
- Official title
- Immunotherapy for Elderly Patients With Chronic Osteoporotic Pain
- Conditions
- Osteoporotic Pain
- Interventions
- Drug: Thymosin Alpha1
- Sponsor
- RenJi Hospital
- Start date
- 2020-11-01
- Primary completion
- 2021-12-31
- Sex
- All
- Age range
- from 60 Years to 80 Years
- Results posted
- No results posted in this snapshot
- Countries
- China
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients suffered osteoporotic pain diagnosed by specialists * VAS scores greater than 5 * Normal reading and understanding ability * Communicate normally * Volunteer to participate Exclusion Criteria: * Mental illness * Serious physical disease * Unwilling to cooperate
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04524169